Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4780725 | 0.94 | SIGMAR1 (0.58) | SIGMAR1LMNAALDH1A1HRH2POLB | |
| SCHEMBL64954 | 0.85 | SIGMAR1 (0.64) | SIGMAR1LMNAALDH1A1HRH2POLB | |
| SCHEMBL22620871 | 0.83 | SIGMAR1 (0.56) | SIGMAR1LMNAALDH1A1POLBGAA | |
| SCHEMBL10678985 | 0.82 | SIGMAR1 (0.58) | SIGMAR1LMNAALDH1A1POLBGAA | |
| SCHEMBL4844073 | 0.82 | SIGMAR1 (0.62) | SIGMAR1LMNAALDH1A1POLBGAA | |
| SCHEMBL4844085 | 0.82 | SIGMAR1 (0.62) | SIGMAR1LMNAALDH1A1POLBGAA | |
| SCHEMBL7573297 | 0.81 | SIGMAR1 (0.56) | SIGMAR1LMNAALDH1A1POLB | |
| SCHEMBL9592391 | 0.79 | SIGMAR1 (0.55) | SIGMAR1LMNA | |
| SCHEMBL6728686 | 0.76 | SIGMAR1 (0.55) | SIGMAR1LMNAALDH1A1POLBGAA | |
| SCHEMBL9592739 | 0.76 | SIGMAR1 (0.60) | SIGMAR1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076924-A1 | Piperazines as P2X7 antagonists | ABBOTT LABORATORIES | 2008-03-27 | — | — | US | disclosed |
| WO-2008005368-A2 | PIPERAZINES AS P2X7 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076924-A1 | Piperazines as P2X7 antagonists | P2RX7, P2RX1, P2RX2 | SIGMAR1 256/4885LMNA 2852/4885ALDH1A1 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.